Dextran‐sulfate‐adsorption of atherosclerotic lipoproteins from whole blood or separated plasma for lipid‐apheresis—Comparison of performance characteristics with DALI and lipidfiltration
- 23 April 2007
- journal article
- clinical trial
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 22 (4) , 215-223
- https://doi.org/10.1002/jca.20135
Abstract
For many years dextran sulfate adsorption (DSA) treatment of separated plasma has been an established technology for low‐density lipoprotein (LDL)‐elimination. Recently a system for the treatment of whole blood based on DSA was introduced into clinical practice. To further characterize DSA treatment of whole blood, the performance characteristics of both DSA modalities were compared at two investigational sites with two alternative LDL apheresis systems being already in routine clinical use. In prospective cross‐over design, DSA whole blood treatment was compared with a whole blood polyacrylate LDL adsorption system (DALI) in one study group. DSA for plasma treatment was compared with Lipidfiltration in cross‐over design in a second study group. In total, 12 patients on chronic LDL apheresis received 169 treatments. Six patients were treated twice with whole blood polyacrylate adsorption and twice with whole blood DSA. LDL‐cholesterol (74.9–78.0%) and lipoprotein (a) (72.1–73.3%) were reduced by both with equal efficacy. DSA achieved a significantly higher reduction rate of fibrinogen. Another six patients were treated eight times with DSA plasma adsorption followed by 16 Lipidfiltration treatments. LDL‐cholesterol (67.0–70.2%) and lipoprotein (a) (69.2–73.7%) were reduced by both with equal efficacy. Fibrinogen was eliminated more efficiently by Lipidfiltration (50.2 vs. 38.5%). DSA proved to be a safe and effective in both treatment modes, for plasma as well as for whole blood. At the discretion of the apheresis specialist, depending upon the status of national approval, DSA of whole blood complements the armamentarium of powerful modalities for extracorporeal elimination of atherosclerotic lipoproteins to meet specific individual, medical, or logistic needs. J. Clin. Apheresis., 2007Keywords
This publication has 32 references indexed in Scilit:
- Low‐density Lipoprotein Apheresis Therapy With a Direct Hemoperfusion Column: A Japanese Multicenter Clinical TrialTherapeutic Apheresis and Dialysis, 2006
- Clinical studies to implement Rheopheresis for age-related macular degeneration guided by evidence-based-medicineTransfusion and Apheresis Science, 2003
- In Vitro Evaluation of Dextran Sulfate Cellulose Beads for Whole Blood Infusion Low‐Density Lipoprotein‐HemoperfusionTherapeutic Apheresis, 2002
- Prospective randomised cross-over comparison of three LDL-apheresis systems in statin pretreated patients with familial hypercholesterolaemiaAtherosclerosis, 2000
- Development of Selective Low‐Density Lipoprotein (LDL) Apheresis System: Immobilized Polyanion as LDL‐Specific Adsorption for LDL Apheresis SystemTherapeutic Apheresis, 2000
- DALI—the first human whole‐blood low‐density lipoprotein and lipoprotein (a) apheresis system in clinical use: procedure and clinical resultsEuropean Journal of Clinical Investigation, 1998
- Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemiaThe American Journal of Cardiology, 1998
- Akutes Nierenversagen bei IgM-Plasmozytom mit Hyperviskositäts-SyndromDeutsche Medizinische Wochenschrift (1946), 1997
- An Effective LDL Removal Filter for the Treatment of HyperlipidemiaArtificial Organs, 1995
- Plasma volume nomograms for use in therapeutic plasma exchangeTransfusion, 1983